Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) has a positive safety and tolerability profile in an open-label, multicenter, phase 3 study in primary immunodeficiency (PI).

Details

Language :

English

ISSN :

00916749

Volume :

145

Database :

Supplemental Index

Journal :

Journal of Allergy & Clinical Immunology

Publication Type :

Academic Journal

Accession number :

142005734

Full Text :

https://doi.org/10.1016/j.jaci.2019.12.824